Invivyd logo

Invivyd

Brand

3.3

Company overview

Invivyd, Inc. (Nasdaq: IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies.In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.#covid19 #immunocompromised
Founded in 2020
New Haven, Connecticut, USA
123 employees (10 in marketing)
www.invivyd.com
31% recommend to a friend
31% positive business outlook

Salaries

Help build salary transparency at Invivyd

Share your compensation anonymously to see full data.

Contribute

People

Hiring activity

Open marketing jobs over time

2 open now

Headcount trend

Company growth over the last 12 months

Headcount +5.9% year over year

Funding

Total funding

$678.5M

Last raise

$125M

Post IPO Equity, 4 months ago

Funding history

Nov 2025

Post IPO Equity Invivyd · $125M

Aug 2025

Post IPO Equity Invivyd · $57.5M

Apr 2025

Post IPO Debt Invivyd · $30M

Apr 2021

Series C Invivyd · $336M

Nov 2020

Series B Invivyd · $80M

Jul 2020

Series A Invivyd · $50M

Audience

Monthly website visitors
14.3K
Month over month+66.6%
Quarter over quarter-13.4%
Top sourceDirect (42%)
Ad budget per month$0.0
Average search rank44.8
Traffic source mix
Direct
42%
Search
35.6%
Social
13.1%
Referral
7.5%
Paid referral
1.5%

LinkedIn followers

Follower count and growth

Total followers

16.8K

12-mo growth

+33.2%

Monthly growth

+9.5%

News

Links

www.invivyd.comLinkedInCrunchbaseX (Twitter)
Glassdoor